Major factors driving the market growth are increasing prevalence of respiratory diseases, growing geriatric population, and technological advancements in respiratory diagnostic systems. On the other hand, rising healthcare costs and reimbursement concerns are the major factors restraining the growth of the respiratory diagnostics market. High potential emerging markets such as Japan, China, India, South Korea, Taiwan, Australia, and Singapore offer significant growth opportunities for the key players in the respiratory diagnostics market.
The global Respiratory Diagnostics Market is projected to reach USD 7.45 Billion by 2021 from USD 5.24 Billion in 2016, at a CAGR of 7.3% from 2016 to 2021. Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=163390459 The global respiratory diagnostics market is segmented on the basis of product and service, test type, disease, end user, and region. On the basis of product and service, the respiratory diagnostics market is segmented into instruments and devices, assays and reagents, and software and services. The instruments and devices segment is expected to account for the largest share of the respiratory diagnostics market in 2016. On the basis of disease, the respiratory diagnostics market is segmented into asthma, chronic obstructive pulmonary disease, lung cancer, tuberculosis, and other diseases. The tuberculosis segment is expected to account for the largest share of the respiratory diagnostics market in 2016. The large share of this segment is primarily attributed to the increase in tobacco smoking and growing air pollution levels. On the basis of test type, the respiratory diagnostics market is broadly classified into mechanical tests, imaging tests, traditional diagnostic tests, and molecular diagnostic tests. In 2016, the traditional diagnostic tests segment is expected to account for the largest share of the respiratory diagnostics market. On the basis of end user, the respiratory diagnostics market is categorized into hospital/clinical laboratories, reference laboratories, physician offices, and other end users (including blood banks, point-of-care testing, patient self-testing, home health agencies, nursing homes, and local public health laboratories). North America is expected to account for the largest share of the global respiratory diagnostics market in 2016, followed by Europe. Read more: - https://www.marketsandmarkets.com/PressReleases/respiratory-diagnostics.asp The respiratory diagnostics market is dominated by established players such as Philips Healthcare (Netherlands), Becton, Dickinson and Company (U.S.), Abbott Laboratories (U.S.), Thermo Fisher Scientific Inc. (U.S.), and Alere, Inc. (U.S.).
0 Comments
The increasing incidence of neurological disorders and technological advancements in nerve repair and regeneration products are the major factors driving the growth of the nerve repair and regeneration market.
The Nerve Repair and Regeneration Market is estimated to register a CAGR of 12.9% to reach USD 10.6 billion by 2022 from USD 5.8 billion in 2017. Based on type, the neurostimulation and neuromodulation devices market is segmented into internal and external neurostimulation devices. The internal neurostimulation devices segment accounted for the larger market share in 2017. These devices help in reducing post-surgical complications and length of hospital stay as well as enable long-term cost savings. Such advantages associated with internal neurostimulation devices are driving their adoption in the market. Download PDF Brochure:-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=883 By end user, the nerve repair and regeneration market is segmented into hospitals & clinics and ambulatory surgery centers. The hospitals & clinics segment accounted for the largest market share in 2017 and is projected to register the highest growth during the forecast period. A large number of nerve repair and neurological procedures performed in hospitals and the growing number of hospitals & clinics, especially in emerging countries, are some of the key factors driving the growth of the nerve repair and regeneration market for this end-user segment. By region, the nerve repair and regeneration market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America accounted for the largest market share in 2017. Factors such as the increasing prevalence of neurological diseases, rapid growth in the geriatric population, favorable reimbursement policies, and the high healthcare expenditure in the region are supporting the growth of the nerve repair and regeneration market in North America. Read more: - https://www.marketsandmarkets.com/PressReleases/nerve-repair-regeneration.asp Prominent players in the nerve repair and regeneration market include AxoGen (US), Baxter (US), Boston Scientific (US), LivaNova (UK), Integra LifeSciences (US), Medtronic (US), Abbott Laboratories (US), Stryker (US), Nevro (US), and Polyganics (Netherlands) Factors such as the rising government funding and growth in the number of genomics projects, decreasing sequencing costs, growing application areas of genomics, and the entry of new players and start-ups in the genomics field are driving the growth of the genomics market during the forecast period.
The Genomics Market is projected to reach USD 35.7 billion by 2024 from USD 18.9 billion in 2019, at a CAGR of 13.5% during the forecast period. Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=613 Based on product & service, the genomics market is segmented into consumables, systems & software, and services. In 2018, the consumables segment accounted for the largest share of this market majorly due to the repeated use of consumables for genomic experiments and the increasing number of research programs by academic institutes and non-profit organizations. By technology, the genomics market is segmented into sequencing, microarray, PCR (polymerase chain reaction), nucleic acid extraction and purification, and other technologies (such as branched DNA analysis, single-cell genomic analysis, and flow cytometry). The PCR segment accounted for the largest share of the genomics market in 2018. Technological advancements, increasing research in the field of genomics, and the lower cost of DNA amplification using PCR are the key factors driving the growth of this market. Based on application, the genomics market is segmented into diagnostics, drug discovery and development, personalized medicine, agriculture and animal research, and other applications (such as forensics and biofuel research). Diagnostics is the largest and the fastest-growing application segment of the genomics market primarily due to the increasing research on diseases such as cancer and genetic disorders and the decreasing cost of sequencing. In 2018, North America was the largest regional market for genomics. The large share of North America in the global genomics market can be attributed to the increasing research funding and government initiatives for promoting precision medicine and the use of GM crops in the US. The Asia Pacific market, on the other hand, is expected to register the highest CAGR during the forecast period. Read More: - https://www.marketsandmarkets.com/PressReleases/genomics.asp Thermo Fisher Scientific, Inc. (US), Illumina, Inc. (US), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (US), Eurofins Scientific (Germany), BGI (China), GE Healthcare (US), Bio-Rad Laboratories, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), and Oxford Nanopore Technologies (UK) are the key players operating in the genomics market. Factors driving the growth of this segment include increasing adoption of urology devices in hospitals and clinics, rising incidence of chronic disorders, and increasing demand for minimally invasive surgeries in urology.
The Urology Devices Market is expected to reach USD 44.37 Billion by 2022 from USD 31.44 Billion in 2017, at a CAGR of 7.1%. Download PDF Brochure:-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=173062212 By disease, the market is segmented into kidney disease, urological cancer and BPH, pelvic organ prolapse. The kidney diseases segment is expected to account for the largest share of the global urology devices in 2017. A large number of products are used in the diagnosis and treatment of this segment which is a major factor responsible for the dominant share of this segment. By product, the urology devices market is classified into instruments and consumables & accessories. The instruments segment is expected to lead the global urology devices market in 2017. On the basis of end user, the urology devices market is categorized into hospitals and clinics, dialysis centers, and other end users. The hospitals and clinics segment is estimated to account for the largest share of the global urology devices market during the forecast period. The heavy burden of urological cancers such as prostate cancer and bladder cancer, along with the accessibility and availability of diagnosis and treatment instruments in hospitals and clinics in a short period of time are the key factors driving the growth of this end-user segment. Based on region, the urology devices market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America is expected to dominate the urology devices market in 2017. Read More: - https://www.marketsandmarkets.com/PressReleases/urology-devices.asp Key players in the urology devices market include Fresenius Medical Care (Germany), Baxter (US), Boston Scientific (US), Olympus (Japan), Richard Wolf (US), KARL STORZ (Germany), Cook Medical (US), Medtronic (US), C. R. Bard (US), Dornier MedTech (Germany), Prometheus Group (US), Medi-Globe (US), Intuitive Surgical (US), Merit Medical Systems (US), Siemens Healthcare (Germany), Stryker (US), ROCAMED (France), Medica (Italy), NOVAmedtek (Turkey), SRS Medical Systems (US), ProSurg (US), Albyn Medical (UK), EMD Medical Technologies (Canada), and Biolitec (Germany). New report examines the Pharmaceutical Membrane Filtration Market worth $8.6 billion by 20247/24/2020 The growth of this market is primarily driven by the growth of the pharmaceutical and biopharmaceutical industry, increasing demand for single-use technologies, and the advancements in nanofiltration techniques.
The global Pharmaceutical Membrane Filtration Market is valued at an estimated USD 5.1 billion in 2019 and is projected to reach USD 8.6 billion by 2024, growing at a CAGR of 11.0% during the forecast period. Download PDF Brochure:-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=255408031 On the basis of product, the pharmaceutical membrane filtration market is segmented into filters, systems, and accessories. Filters formed the largest product segment in this market owing to the high and growing use of different types of membrane filters for various filtration applications in the biopharmaceutical manufacturing industry. On the basis of application, the pharmaceutical membrane filtration market is segmented into final product processing, raw material filtration, cell separation, water purification, and air purification. Final product processing was the largest application segment in the pharmaceutical membrane filtration market in 2018. The global pharmaceutical membrane filtration market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. In 2018, North America was the largest market for pharmaceutical membrane filtration, followed by Europe. The large share of North America can be attributed to several factors, such as the presence of key biopharmaceutical manufacturing facilities in the region and the significant spending on research and development activities in the US. Read More: - https://www.marketsandmarkets.com/PressReleases/pharmaceutical-membrane-filtration.asp The major companies operating in the pharmaceutical membrane filtration market include Merck Millipore (Germany), Danaher (US) and Sartorius Stedim Biotech (France). Hemodialysis & Peritoneal Dialysis Market statistics and research analysis released in latest report7/23/2020 Growth in this market is driven by the increasing number of ESRD patients, growing prevalence of diabetes & hypertension, shortage of organ donors and risks associated with transplant, technological advancements and new product launches, and rising R&D expenditure for developing new dialysis products.
The Hemodialysis & Peritoneal Dialysis Market is projected to reach USD 99.2 billion by 2024 from USD 74.2 billion in 2019, at a CAGR of 6.0% Recent Developments
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1279 The global hemodialysis market is broadly categorized into two segments, namely, hemodialysis products and hemodialysis services market. The hemodialysis products market includes machines (center-use & home-use machines) & consumables (dialyzers, access products, bloodlines, dialysates, and other consumables). The hemodialysis services (including in-center & home- hemodialysis services) segment is expected to account for the largest share of the hemodialysis market. The increasing number of dialysis centers coupled with the growing prevalence of ESRD is the major factor driving the growth of the hemodialysis services market. The peritoneal dialysis market, by modality, includes continuous ambulatory peritoneal dialysis (CAPD) and automated peritoneal dialysis (APD). The APD segment is expected to grow at the highest CAGR owing to its several advantages over CAPD, such as daytime freedom for patients, fewer connections and disconnections (and hence a lower probability of peritonitis), and improved quality of life. Being automated, APD is also the preferred dialysis treatment for the elderly and children. Regional Analysis:-Based on region, the hemodialysis and peritoneal dialysis market has been segmented into four major regions, namely, North America, Europe, Asia Pacific, and the Rest of the World. North America is expected to account for the largest share of the hemodialysis and peritoneal dialysis market in 2019. The higher per capita income as compared to other regions, favorable reimbursement scenario, and increasing demand for dialysis procedures are propelling the growth of the market. Read more: - https://www.marketsandmarkets.com/PressReleases/dialysis.asp Key Players:-The major players operating in the global hemodialysis and peritoneal dialysis market are Fresenius Medical Care AG & Co. KGaA (Germany), DaVita Healthcare Partners, Inc. (US), Baxter International, Inc. (US), and B. Braun Melsungen AG (Germany). The report Pharmaceutical Filtration Market provides a detailed overview of major drivers, restraints, challenges, opportunities, current market trends and strategies impacting the global market along with estimates and forecast of revenue.
Market growth is primarily driven by factors such as growing production of large molecules and biologics, technological advancements in nanofibers, growth in the generics market, and regulatory mandates for cleanrooms in pharmaceutical production. Other factors supporting market growth include an increase in R&D spending by biopharmaceutical companies to offer a strong biologics pipeline. The global Pharmaceutical Filtration Market is poised to reach USD 22.71 Billion by 2021 from USD 13.73 Billion in 2016, at a CAGR of 10.6% from 2016 to 2021. Download PDF Brochure:-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=209343847 The global pharmaceutical filtration market is segmented on the basis of product, technique, application, scale of operation, and region. On the basis of product, the pharmaceutical filtration market is segmented into membrane filters, prefilters and depth media filters, cartridge & capsule filters, single-use systems, filter holders, filtration accessories, and other products. In 2016, the membrane filters segment accounted for the largest share of the market. This segment is also expected to register the highest CAGR during the forecast period. Based on application, the final product-processing segment is expected to register the highest CAGR during the forecast period owing to the rapidly growing biologics and generic drug production coupled with the presence of stringent regulatory guidelines to maintain a clean and safe manufacturing environment. North America accounted for the largest share of the global pharmaceutical filtration market in 2016, followed by Europe. Stringent regulatory guidelines to provide safe drugs is encouraging the use of pharmaceutical filtration products and the presence of a large number of market players are propelling the growth of the North American pharmaceutical filtration market. The Asian region is expected to register the highest CAGR in the forecast period. Read More: - https://www.marketsandmarkets.com/PressReleases/pharmaceutical-filtration.asp The pharmaceutical filtration market is dominated by established players such as Merck KGaA (Germany), GE Healthcare (U.S.), Pall Corporation (U.S.), Parker Hannifin Corporation (U.S.), and Sartorius Stedim Biotech S.A. (France). The growth of the market is attributed favorable reimbursement scenario and strong government support in selected countries, technological advancements in insulin delivery devices, and growing diabetic population. Increasing research and development activities and increase in diabetes-related health expenditure in emerging economies are expected to offer significant growth opportunities for manufacturers in the coming years.
The Insulin Delivery Devices Market is expected to reach USD 17.8 billion by 2021 from USD 11.5 billion in 2016, at a CAGR of 9.1% during the forecast period. Download PDF Brochure:-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=107632092 Based on type, the insulin delivery devices market is categorized into pens, pumps, pen needles, syringes, and others (insulin inhalers, transdermal patches, and insulin jet injectors, among others). In 2016, the pens segment is expected to command the largest share of the insulin delivery devices market. The pens segment is further divided into reusable and disposable pens. The reusable pens segment is estimated to command the largest share of the insulin pens market in 2016. This large share can be attributed to lower price compared to disposable pens; availability of reimbursement in selected countries, and increasing adoption of insulin pens in the Asia-Pacific region. By end user, the insulin delivery devices market is segmented into patients/homecare and hospitals & clinics. The patients/homecare segment is estimated to command the largest share of the market in 2016 and is expected to grow at the highest CAGR during the forecast period. In 2016, North America is expected to account for the largest share of the global insulin delivery devices market. North America’s leadership position in the market can be attributed to the rising prevalence of diabetes and favorable reimbursement scenarios in the US and Canada, awareness activities, venture capital investments and issuance of IPOs in the US, and regulations for the usage of safety-engineered needles in Canada. Read More: - https://www.marketsandmarkets.com/PressReleases/insulin-delivery-device.asp The insulin delivery devices market is highly competitive with the presence of several small and big players. Some of the players in the insulin delivery devices market include Becton, Dickinson and Company (US), Novo Nordisk A/S (Denmark), Ypsomed Holding AG (Switzerland), Medtronic plc (Ireland), Animas Corporation (US), Tandem Diabetes Care, Inc. (US), Sanofi (France), Biocon Ltd. (India), Eli Lilly and Company (US), and Insulet Corporation (US). Factors driving the growth of this market are the rapid growth in the pharmaceutical and biotechnology industries, R&D investments and government support. Mycoplasma testing is carried out in the research and production of all biopharmaceutical products. Growth in the pharmaceutical and biotechnology sector across the globe serves as a direct driver for associated markets such as mycoplasma testing.
The Mycoplasma Testing Market is expected to reach USD 943.4 Million by 2022 from USD 523.3 Million in 2017, at a CAGR of 12.5%. Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=136509856 On the basis of products, the mycoplasma testing market is segmented into kits & reagents, instruments, and services. The kits & reagents segment is expected to dominate the global mycoplasma testing market in 2017. The frequent purchase of these consumables as compared to instruments and increasing use of kit-based techniques are key factors driving the growth of this segment. Based on technique, the mycoplasma testing market is segmented into PCR, ELISA, direct assays, indirect assays, DNA staining, microbial culture techniques, and enzymatic methods. In 2017, the PCR technique segment is expected to account for the largest share of the mycoplasma testing market, by technique. Based on region, the mycoplasma testing market is segmented into North America, Europe, Asia, and Rest of the World (RoW). North America is expected to dominate the mycoplasma testing market in 2017 on account of the high adoption rate of novel technologies and a large number of life science research studies conducted in this region. Read More: - https://www.marketsandmarkets.com/PressReleases/mycoplasma-testing.asp Key players in the mycoplasma testing market include Thermo Fisher Scientific Inc. (U.S.), Charles River Laboratories International, Inc. (U.S.), Lonza Group Ltd. (Switzerland), Merck KGaA (Germany), Roche Diagnostics (Switzerland), SGS S.A. (Switzerland), American Type Culture Collection (U.S.) and Bionique Testing Laboratories, Inc. (U.S.). Major factors driving the growth of this market include growing need for effective and early diagnosis, rising global prevalence of targeted diseases coupled with an aging population, increasing preference for minimally invasive diagnostic procedures, increasing benefits of CT scans over other imaging modalities, and technological advancements.
The Global CT Scanner Market is projected to reach USD 6.20 Billion by 2022, at a CAGR of 5.4% during the forecast period. Download PDF Brochure: - http://www.marketsandmarkets.com/pdfdownload.asp?id=184364345 Major Market Developments:
Based on type, the CT scanners market is divided into stationary and portable CT scanners. Portable CT scanners segment is poised to grow faster than the other segment due to increasing number of device installations across major markets, growing application horizons, and the lower switching costs provided by portable CT scanners. Geographical Analysis:- Geographically, the CT scanner market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. Read more: - https://www.marketsandmarkets.com/PressReleases/ct-scanner.asp Top Key players:- The major players in the CT scanner market are Koninklijke Philips N.V. (Netherlands), GE Healthcare (U.S.), Toshiba Corporation (Japan), Siemens AG (Germany), Hitachi Ltd. (Japan), Shimadzu Corporation (Japan), Samsung Electronics Co., Ltd. (South Korea), Carestream Health Inc. (U.S.), and PointNix Co. Ltd (South Korea). |
AuthorWe are providing and consulting the healthcare Industry Research Report. Archives
March 2022
Categories |